







| Table 3 The three com | mercially available LIFAs | | | | |
|---|---|---|---------------|------------------------|--|
| Name | Manufacturer/vial contents | Mean diameter | Shell | Gas | Contraindication |
| Lumason (sulfur hexafluoride lipid-type A microspheres) | Bracco Diagnostics, 5 mL | 1.5–2.5 μm (maximum 20 μm, 99% ≤10 μm) | Phospholipid | Sulfur Hexafluoride | Allergy to sulfur hexafluoride |
| Definity (perflutren lipid microsphere) | Lantheus Medical Imaging, 1.5 mL | 1.1–3.3 μm (maximum 20 μm, 98% <10 μm) | Phospholipid | Perflutren | Allergy to perflutren |
| Optison (perflutren protein type-A microspheres) | GE Healthcare, 3.0 mL | 3.0–4.5 μm (maximum 32 μm, 95% <10 μm) | Human albumin | Perflutren | Allergy to perflutrent blood products |
| | size: 1- 8 μ biodegradable scatter US | FDA approved | – Lumason | (Sonovue) | , Definity an |
| | Shell: • protein • lipid • surfactant | Europe EMA ap | proved – S | onovue | |



CE aim to enhance non linear signals from bubbles while suppressing linear signals (noise) from myocardium, i.e. increase signal to noise ratio, by using special imaging mode.









ASE 2018: Clinical Applications of UEAs (Adult Cardiac Applications)

1. Left Ventricular Opacification (LVO) - only FDA approved use

2. Myocardial Perfusion Echocardiography (MCE) - Off label , still recommended by ASE 2018

3. Sonoporation - Targeted drug and gene delivery - Research

> Changi General Hospit



Changi General Hospi

| 1. Updates on Quantification of LV volumes, LVEF, and RWM | | | | | |
|--|---|--|--|--|--|
| Clinical Applications of Ultrasonic Enhancing Agents in Echocardiography: 2018 American Society of Echocardiography Guidelines Update | | | | | |
| Key Points and Recommendations | | | | | |
| As per 2008 ASE guidelines, for nontine re should be used when two gumes UV segme the assessment of UV instributions and the start and the start of UV instribution and the start anging to determ proceedings of contents and for volume and ejection fraction measures U thrasonate detainments the proposite of UV content of UVF 3 is important to proposite of UV volumes (ALO # 8.6. UV volumes education (ALO # 8.6. UV volumes education (ALO # 8.6. UV volumes (and the VIII and therefore 2015 should be applied with caucion when educ emerginal anging of UVF does not appare to measure without (DV and method and applied with an experiment of UVF does not appare to measure without (DV and method and applied with a strangesting and the strangesting and applied with a strangesting and applied with a strangesting and applied with a strangesting and applied with a strangesting and applied with a strangesting applie | As per 2008 ASE guidelines, for routine resting echo UEAs should be used when 2 or more LV segments cannot be visualized adequately for the assessment of LV function (LVEF and RWM) and/or study indication requires accurate analysis of RWM (COR 1, LOE A) Ultrasound enhancement should be used in ALL natients in whom quantitative assessment of | | | | |
| As per section III of the 2014 ASE guidelines sion or a low velume (cs) and holes injects is recommended along with VIAI imaging to tion and basal segment attenuation. | LVEF is important to prognosis or management of the clinical cond - kiv ICD/CRT imaging techniqi - cardiotoxicity from optimal LVO (CC - valve disease for intervention | | | | |























Key Points and Recommendations for the Use of 2. UEAs in Detecting LV Cavity Abnormalities and Intracardiac Masses 1. Ultrasound enhancement shuld be used in patients in whom IV thrombus cannot be ruled in or out with noncoltast echocardiography (COR I, LOE B-NR). 2. Ultrasound enhancement should be used for LV thrombus, and aneur (COR II, IV Sendoaneurysm, assess vascularity of 4. Ultrasoun with uner S. Ultrasound the considered for LV thrombus, and aneur (COR I, IV 5. Ultrasound ACM, LV pseudoaneurysm, assess vascularity of 3. Ultrasound appendage with ULMI. 3. US enhancement should be considered during TEE whenever the atrial appendage has significant spontaneous contrast or cannot be adequately visualized with unenhanced imaging (COR IIa, LOE B-NR)



















































Contrast is SAFE

- Since black box by FDA in 2007, innumerous studies in rest and stress echo, critically ill patients, pulmonary hypertension demonstrated safety.
- Contraindication of right to left shunt removed in 2017
- Emerging safety data in LVAD and ECMO patients

Current Contraindications:

- known hypersensitivity to products
- Not for intra-arterial injections
- Not advisable in pregnant women

Current BBW:

 Risk of serious cardiopulmonary reactions in patients with unstable cardiopulmonary conditions are rare and typically occurs within 30 mins









Conclusions

- LVO at rest (2 or more segments not visualized) and stress echo (any segment not visualized) remains the only approved indication for UEA by FDA.
- Growing data show myocardial perfusion study with UEA is feasible clinically and adds incremental value to wall motion.
- UEA is safe to use. SAE is about 1 in 10000. Users should be watchful for possible anaphylactoid reactions.

Changi General Hospital Thank you!

